THE EFFECT OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (bDMARDs) IN TARGETING DISEASE REMISSION IN AXIAL SPONDYLOARTHRITIS (axSpA): A SYSTEMATIC LITERATURE REVIEW (SLR)

被引：0
|
作者：
Cruz-Machado, A. R. [1 ,2 ]
Manica, S. R. [3 ]
Silva, J. L. [4 ]
Pimentel-Santos, F. M. [3 ]
Tavares-Costa, J. [4 ]
Vieira-Sousa, E. [1 ,2 ]
机构：
[1] Hosp Santa Maria, CHLN, Serv Reumatol & Doencas Osseas Metab, Lisbon, Portugal
[2] IMM, UIR, Lisbon, Portugal
[3] Ctr Hosp Lisboa Ocidental, Hosp Egas Moniz, Rheumatol Dept, Lisbon, Portugal
[4] Rheumatol Dept, Unidade Local Saude Alto Minho, Ponte do Lima, Portugal
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P88
引用
收藏
页码：731 / 731
页数：1
相关论文
共 50 条
  • [41] Adherence to biologic disease-modifying antirheumatic drugs in adult patients with rheumatic diseases
    Fazaa, Alia
    Makhlouf, Yasmine
    Ben Ouhiba, Amad
    Miladi, Saoussen
    Sellami, Mariem
    Ouenniche, Kmar
    Souabni, Leila
    Kassab, Salma
    Chekili, Selma
    Zakraoui, Leith
    Ben Abdelghani, Kawther
    Laatar, Ahmed
    THERAPIE, 2021, 76 (05): : 467 - 474
  • [42] Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIR
    Kedra, Joanna
    Granger, Benjamin
    Emilie, Stephanie
    Gaujoux-Viala, Cecile
    Rat, Anne-Christine
    Combe, Bernard
    Fautrel, Bruno
    JOINT BONE SPINE, 2021, 88 (01)
  • [43] Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children
    Cron, Randy Q.
    CURRENT OPINION IN RHEUMATOLOGY, 2022, 34 (05) : 274 - 279
  • [44] Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk
    Sendaydiego, Xavier
    Gold, Laura S.
    Dubreuil, Maureen
    Andrews, James S.
    Reid, Pankti
    Liew, David F. L.
    Goulabchand, Radjiv
    Singh, Abha Goyal
    Hughes, Grant C.
    Pioro, Mathilde
    Sparks, Jeffrey A.
    Jarvik, Jeffrey G.
    Singh, Siddharth
    Liew, Jean W.
    Singh, Namrata
    JAMA NETWORK OPEN, 2024, 7 (11)
  • [45] The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation
    Goralczyk, Alicja
    Kolossa, Katarzyna
    Waszczak-Jeka, Marzena
    Adamczak, Rafal
    Jeka, Slawomir
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2020, 37 (03): : 306 - 312
  • [46] ANNUAL TREATMENT COST OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS
    Hosseini, R.
    Brown, L. M.
    Fleming, M.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2024, 27 (06) : S110 - S110
  • [47] Adherence to Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis A Narrative Review of the Literature
    Salt, Elizabeth
    Frazier, Susan K.
    ORTHOPAEDIC NURSING, 2010, 29 (04) : 260 - 275
  • [48] Combination of methotrexate with oral disease-modifying antirheumatic drugs in psoriatic arthritis: a systematic review
    Hsieh, Tyng-Shiuan
    Tsai, Tsen-Fang
    IMMUNOTHERAPY, 2024, 16 (02) : 115 - 130
  • [49] Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review
    Calvo Alen, Jaime
    Perez, Trinidad
    Romero Yuste, Susana
    Ferraz-Amaro, Ivan
    Alegre Sancho, Juan Jose
    Pinto Tasende, Jose Antonio
    Maceiras Pan, Francisco
    Carlos Quevedo, Juan
    Vanesa Hernandez-Hernandez, M.
    Hidalgo Calleja, Cristina
    San Martin Alvarez, Alejandro
    Tevar Sanchez, Maria Isabel
    Sanmarti, Raimon
    REUMATOLOGIA CLINICA, 2020, 16 (05): : 324 - 332
  • [50] Nonsteroidal Antiinflammatory Drugs as Potential Disease-Modifying Medications in Axial Spondyloarthritis
    Wang, Runsheng
    Bathon, Joan M.
    Ward, Michael M.
    ARTHRITIS & RHEUMATOLOGY, 2020, 72 (04) : 518 - 528
12345